Demographic characteristics and clinical information of subjects
| Patient ID . | Disease (grade) . | Chemotherapy drugs history (drug doses) . | Radiation therapy dose . | Time since chemotherapy and radiation, wks . | Race . | Sex . | Age, y . |
|---|---|---|---|---|---|---|---|
| Breast carcinoma-chemotherapy group | |||||||
| 4915 | Breast carcinoma (T2, N1/2, M0) | 4 cycles of adriamycin (105 mg) + Cytoxan (1050 mg) | NA | 18 | White | Female | 70 |
| 8871 | Breast carcinoma (grade 1) | 4 cycles of adriamycin (103 mg) + Cytoxan (1000 mg), followed by 4 cycles of Taxol (300 mg) and Neulasta (6 mg) | NA | 25 | White | Female | 49 |
| 4700 | Breast carcinoma (T3, N1, M0) | 4 cycles of adriamycin + Cytoxan (performed off site; dosing information not available) | NA | 14 | Unknown | Female | 57 |
| 9942 | Breast carcinoma (T4, N1c, M0) | 4 cycles of idamycin + Cytoxan (performed off site; dosing information not available) | NA | 14 | White | Female | 59 |
| 9576 | Breast carcinoma (stage not available) | 4 cycles of FU (280 mg) + epirubicin (140 mg) + Cytoxan (920 mg) + Herceptin (140 mg) followed by weekly Herceptin (140 mg) + Taxol (150 mg) for 12 wks | NA | 30 | White | Female | 38 |
| 9493 | Breast carcinoma (T2, N1, M0) | 3 cycles of Taxol dose 2 (300 mg) + Neulasta (6 mg), followed by adriamyacin (102 mg) + Cytoxan (1020 mg) + Neulasta (6 mg) | NA | 25 | White | Female | 51 |
| 1594 | Breast carcinoma (T3, N3c, M0) | 4 cycles of adriamyacin and Cytoxan + Neulasta (6 mg), followed one Taxol (175 mg/m2) | NA | 16 | Unknown | Female | 36 |
| 7204 | Breast carcinoma (T2, N0, M0) | 4 cycles of Taxotere (130 mg) and Cytoxan (1044 mg) + Neulasta (6 mg) | NA | 22 | White | Female | 68 |
| 4060 | Breast carcinoma (T2, N1) | Femar 2.5 mg/d for 13 wks, followed by 1 cycle of Taxotere (130 mg), Cytoxan (1000 mg), and 1 cycle of Nuelasta (6 mg) | NA | 23 | White | Female | 64 |
| 3438 | Breast carcinoma (T3, N1, grade 2) | 4 cycles of adriamycin, Cytoxan (dosing information not available), followed by 12 doses of weekly Paclitaxel (dosing information not available), followed by 1 cycle of Neulasta (6 mg), followed by weekly Taxol (122 mg) for 12 wks | NA | 26 | White | Female | 42 |
| Breast carcinoma-control group (no chemoradiotherapy before LN biopsy) | |||||||
| 4914 | Breast carcinoma (T2.5, N0, M0) | NA | NA | NA | White | Female | 32 |
| 3873 | Breast carcinoma (T2, N0, M0) | NA | NA | NA | White | Female | 40 |
| 9492 | Breast carcinoma (pT1c, N0, M0) | NA | NA | NA | White | Female | 47 |
| 5333 | Breast carcinoma (T1c, N0, Mx) | NA | NA | NA | White | Female | 76 |
| 4197 | Breast carcinoma (T2, N0, M0) | NA | NA | NA | Black | Female | 51 |
| 4934 | Breast carcinoma (T2, N0, M0) | NA | NA | NA | White | Female | 39 |
| 2021 | Breast carcinoma (grade 1) | NA | NA | NA | White | Female | 62 |
| 1979 | Breast carcinoma (T1c, N0, M0) | NA | NA | NA | White | Female | 57 |
| 1626 | Breast carcinoma (pT1c, N0(i-)(sn), MX) | NA | NA | NA | White | Female | 42 |
| 4131 | Breast carcinoma pTis, N0, MX G2) | NA | NA | NA | White | Female | 44 |
| Esophageal carcinoma-chemoradiotherapy group | |||||||
| 5491 | Esophageal carcinoma (stage not available) | Treatment performed off site; information not available | NA | 11 | White | Male | 46 |
| 3445 | Esophageal adenocarcinoma (stage not available) | Cisplatin and infusional 5-FU (performed off site; dosing information not available) | NA | Unknown | Unknown | Male | 66 |
| 9921 | Adenocarcinoma of the gastroesophageal junction (T3, N0, M0) | Epirubicin (50 mg/m2), oxaliplatin (130 mg/m2) and Xeloda (625 mg/m2), followed by 1 cycle Neulasta (6 mg) | NA | 23 | White | Male | 75 |
| 2670 | Distal esophageal adenocarcinoma (T3, N0, M0) | 2 cycles of concurrent chemotherapy (performed off site; drug information not available) | Area of tumor involvement and regional LNs received a dose of 4500 cGy in 25 fractions using a four-field technique with 10 MV photons | 11 | White | Male | 56 |
| 2409 | Adenocarcinoma of the gastroesophageal junction (T3, N1-2) | 4 cycles of cisplatin (75 mg/m2), 5-FU (2300 mg/d) | 25 fractions 1.8 Gy to gastroesophageal junction, regional LNs and margin; 50.4 Gy total dose to primary site | 27 | White | Male | 40 |
| 7852 | Esophageal carcinoma (stage not available) | 3 cycles carboplatin, taxol, and 5-FU, followed by concurrent cisplatin and 5-FU (performed off site; dosing information not available) | Dosing information not available | Unknown | White | Male | 51 |
| 5595 | Esophageal carcinoma (stage not available) | Treatment performed off site; information not available | Dosing information not available | 22 | White | Male | 59 |
| 2341 | Esophageal adenocarcinoma (T3, N1, MX) | 2 cycles of Cisplatin (75 mg/m2), 5-FU (100 mg/m2) | Dosing information not available | 26 | White | Male | 78 |
| 7932 | Esophageal adenocarcinoma (T3, N1, M0) | 3 cycles of Carboplatin (658 mg), Taxol (125 mg) | Radiation 25 fractions with dose of 45 Gy | 31 | White | Male | 54 |
| Esophageal carcinoma-control group (no chemoradiotherapy before LN biopsy) | |||||||
| 6669 | Moderately differentiated adenocarcinoma (T1, N0) | NA | NA | NA | White | Male | 55 |
| 4818 | Esophageal leiomyoma (T3, N0) | NA | NA | NA | White | Male | 48 |
| 4917 | Adenocarcinoma, moderately to poorly differentiated (T2, N0) | NA | NA | NA | White | Male | 75 |
| 4307 | Adenocarcinoma, poorly differentiated, with papillaryand clear cell features (T2, N0) | NA | NA | NA | White | Female | 78 |
| 5924 | Adenocarcinoma, poorly differentiated (stage not available) | NA | NA | NA | White | Female | 44 |
| 3159 | Moderately differentiated adenocarcinoma (T1, N0) | NA | NA | NA | White | Male | 57 |
| 6067 | Moderately to poorly differentiated adenocarcinoma (stage not available) | NA | NA | NA | Not available | Female | 67 |
| 4602 | Multifocal high-grade dysplasia (stage not available) | NA | NA | NA | White | Male | 51 |
| 6669 | Moderately differentiated adenocarcinoma (T1, N0) | NA | NA | NA | White | Male | 55 |
| Patient ID . | Disease (grade) . | Chemotherapy drugs history (drug doses) . | Radiation therapy dose . | Time since chemotherapy and radiation, wks . | Race . | Sex . | Age, y . |
|---|---|---|---|---|---|---|---|
| Breast carcinoma-chemotherapy group | |||||||
| 4915 | Breast carcinoma (T2, N1/2, M0) | 4 cycles of adriamycin (105 mg) + Cytoxan (1050 mg) | NA | 18 | White | Female | 70 |
| 8871 | Breast carcinoma (grade 1) | 4 cycles of adriamycin (103 mg) + Cytoxan (1000 mg), followed by 4 cycles of Taxol (300 mg) and Neulasta (6 mg) | NA | 25 | White | Female | 49 |
| 4700 | Breast carcinoma (T3, N1, M0) | 4 cycles of adriamycin + Cytoxan (performed off site; dosing information not available) | NA | 14 | Unknown | Female | 57 |
| 9942 | Breast carcinoma (T4, N1c, M0) | 4 cycles of idamycin + Cytoxan (performed off site; dosing information not available) | NA | 14 | White | Female | 59 |
| 9576 | Breast carcinoma (stage not available) | 4 cycles of FU (280 mg) + epirubicin (140 mg) + Cytoxan (920 mg) + Herceptin (140 mg) followed by weekly Herceptin (140 mg) + Taxol (150 mg) for 12 wks | NA | 30 | White | Female | 38 |
| 9493 | Breast carcinoma (T2, N1, M0) | 3 cycles of Taxol dose 2 (300 mg) + Neulasta (6 mg), followed by adriamyacin (102 mg) + Cytoxan (1020 mg) + Neulasta (6 mg) | NA | 25 | White | Female | 51 |
| 1594 | Breast carcinoma (T3, N3c, M0) | 4 cycles of adriamyacin and Cytoxan + Neulasta (6 mg), followed one Taxol (175 mg/m2) | NA | 16 | Unknown | Female | 36 |
| 7204 | Breast carcinoma (T2, N0, M0) | 4 cycles of Taxotere (130 mg) and Cytoxan (1044 mg) + Neulasta (6 mg) | NA | 22 | White | Female | 68 |
| 4060 | Breast carcinoma (T2, N1) | Femar 2.5 mg/d for 13 wks, followed by 1 cycle of Taxotere (130 mg), Cytoxan (1000 mg), and 1 cycle of Nuelasta (6 mg) | NA | 23 | White | Female | 64 |
| 3438 | Breast carcinoma (T3, N1, grade 2) | 4 cycles of adriamycin, Cytoxan (dosing information not available), followed by 12 doses of weekly Paclitaxel (dosing information not available), followed by 1 cycle of Neulasta (6 mg), followed by weekly Taxol (122 mg) for 12 wks | NA | 26 | White | Female | 42 |
| Breast carcinoma-control group (no chemoradiotherapy before LN biopsy) | |||||||
| 4914 | Breast carcinoma (T2.5, N0, M0) | NA | NA | NA | White | Female | 32 |
| 3873 | Breast carcinoma (T2, N0, M0) | NA | NA | NA | White | Female | 40 |
| 9492 | Breast carcinoma (pT1c, N0, M0) | NA | NA | NA | White | Female | 47 |
| 5333 | Breast carcinoma (T1c, N0, Mx) | NA | NA | NA | White | Female | 76 |
| 4197 | Breast carcinoma (T2, N0, M0) | NA | NA | NA | Black | Female | 51 |
| 4934 | Breast carcinoma (T2, N0, M0) | NA | NA | NA | White | Female | 39 |
| 2021 | Breast carcinoma (grade 1) | NA | NA | NA | White | Female | 62 |
| 1979 | Breast carcinoma (T1c, N0, M0) | NA | NA | NA | White | Female | 57 |
| 1626 | Breast carcinoma (pT1c, N0(i-)(sn), MX) | NA | NA | NA | White | Female | 42 |
| 4131 | Breast carcinoma pTis, N0, MX G2) | NA | NA | NA | White | Female | 44 |
| Esophageal carcinoma-chemoradiotherapy group | |||||||
| 5491 | Esophageal carcinoma (stage not available) | Treatment performed off site; information not available | NA | 11 | White | Male | 46 |
| 3445 | Esophageal adenocarcinoma (stage not available) | Cisplatin and infusional 5-FU (performed off site; dosing information not available) | NA | Unknown | Unknown | Male | 66 |
| 9921 | Adenocarcinoma of the gastroesophageal junction (T3, N0, M0) | Epirubicin (50 mg/m2), oxaliplatin (130 mg/m2) and Xeloda (625 mg/m2), followed by 1 cycle Neulasta (6 mg) | NA | 23 | White | Male | 75 |
| 2670 | Distal esophageal adenocarcinoma (T3, N0, M0) | 2 cycles of concurrent chemotherapy (performed off site; drug information not available) | Area of tumor involvement and regional LNs received a dose of 4500 cGy in 25 fractions using a four-field technique with 10 MV photons | 11 | White | Male | 56 |
| 2409 | Adenocarcinoma of the gastroesophageal junction (T3, N1-2) | 4 cycles of cisplatin (75 mg/m2), 5-FU (2300 mg/d) | 25 fractions 1.8 Gy to gastroesophageal junction, regional LNs and margin; 50.4 Gy total dose to primary site | 27 | White | Male | 40 |
| 7852 | Esophageal carcinoma (stage not available) | 3 cycles carboplatin, taxol, and 5-FU, followed by concurrent cisplatin and 5-FU (performed off site; dosing information not available) | Dosing information not available | Unknown | White | Male | 51 |
| 5595 | Esophageal carcinoma (stage not available) | Treatment performed off site; information not available | Dosing information not available | 22 | White | Male | 59 |
| 2341 | Esophageal adenocarcinoma (T3, N1, MX) | 2 cycles of Cisplatin (75 mg/m2), 5-FU (100 mg/m2) | Dosing information not available | 26 | White | Male | 78 |
| 7932 | Esophageal adenocarcinoma (T3, N1, M0) | 3 cycles of Carboplatin (658 mg), Taxol (125 mg) | Radiation 25 fractions with dose of 45 Gy | 31 | White | Male | 54 |
| Esophageal carcinoma-control group (no chemoradiotherapy before LN biopsy) | |||||||
| 6669 | Moderately differentiated adenocarcinoma (T1, N0) | NA | NA | NA | White | Male | 55 |
| 4818 | Esophageal leiomyoma (T3, N0) | NA | NA | NA | White | Male | 48 |
| 4917 | Adenocarcinoma, moderately to poorly differentiated (T2, N0) | NA | NA | NA | White | Male | 75 |
| 4307 | Adenocarcinoma, poorly differentiated, with papillaryand clear cell features (T2, N0) | NA | NA | NA | White | Female | 78 |
| 5924 | Adenocarcinoma, poorly differentiated (stage not available) | NA | NA | NA | White | Female | 44 |
| 3159 | Moderately differentiated adenocarcinoma (T1, N0) | NA | NA | NA | White | Male | 57 |
| 6067 | Moderately to poorly differentiated adenocarcinoma (stage not available) | NA | NA | NA | Not available | Female | 67 |
| 4602 | Multifocal high-grade dysplasia (stage not available) | NA | NA | NA | White | Male | 51 |
| 6669 | Moderately differentiated adenocarcinoma (T1, N0) | NA | NA | NA | White | Male | 55 |
If the patients also had radiation therapy, the LN biopsy is included in the radiation field.
NA indicates not applicable; and 5-FU, 5-fluorouracil.